Private Care SPRING 2019
PAVING THE WAY Meet the expert who’s driving forward holistic breast cancer care
Four-star success at the LaingBuisson Awards
RMPC24_p01_cover_v2.0.indd 1
21/02/2019 12:49
SPRING 2019
PRIVATE CARE AT THE ROYAL MARSDEN
THE FACTS
7
categories in which Private Care was shortlisted at the LaingBuisson Awards 2018
WELCOME As the Managing Director of P rivate Care at The Royal Marsden, I’ m pleased to introduce the latest issue of P rivate Care magaz ine. In this edition, we celebrate winning four L aingB uisson Awards, and the teams and individuals whose hard work they recognised. As part of this, our Consultant F ocus delves into the work of our L aingB uisson-nominated Rising Star, Dr Alistair Ring, and his endeavours to improve the q uality of life and meet the holistic needs of breast cancer patients. In our feature on the safety benefits of private care in an N H S setting, Chief P harmacist J atinder H archowal – also a L aingB uisson-nominated Rising Star – takes us through the strict governance that Royal Marsden private consultants must adhere to. We also pay our respects to P rofessor Martin G ore CB E, who passed away unexpectedly in J anuary. P rofessor G ore spent 4 0 years of his career at The Royal Marsden, and was one of the world’ s leading cancer experts. H is vast knowledge saved the lives of countless people, and he’ ll be missed by all who knew him. Shams Maladwala Managing Director of Private Care
ON THE COVER Dr Alistair Ring, Consultant in Medical Oncology in the Breast Unit
350
nominations reviewed by LaingBuisson judges
27
independent judges sat on panels to choose the award winners
2nd
year in a row that we have won LaingBuisson’s Private Hospital award
4
awards won at the 2018 LaingBuisson Awards
2
members of Royal Marsden staff nominated for the LaingBuisson Rising Star award
FIND OUT MORE
For referrals and enquiries, call 020 7811 8111 or email privatepatients@rmh.nhs.uk
2 Private Care magazine
RMPC24_p02-03_Update_v4.0.indd 2
13/02/2019 13:10
U P DAT E
PRIVATE CARE’S FANTASTIC FOUR
IN UNPRECEDENTED SUCCESS, The Royal Marsden Private Care has won four prizes at the 2018 LaingBuisson Awards, including the award for best Private Hospital for the second year running. Now in their 13th year, these prestigious awards recognise excellence in private
healthcare and social care. The finalists were chosen by independent judges from more than 350 nominations, and The Royal Marsden was the only organisation to win four awards. These awards are a testament to our unique Private Care and NHS model, which
THAT WINNING FEELING Our successful Private Care team at the LaingBuisson Awards
enables us to reinvest revenue generated by Private Care into the hospital for the benefit of all our patients. Shams Maladwala, Managing Director of Private Care, said: “Winning these high-profile awards and being shortlisted for a further three in two other categories reflects the fantastic work that all staff do for all our patients, every day.” Turn to page 8 to read more about the aspects of The Royal Marsden’s worldleading work that helped us to achieve awards success.
TALKING POINTS “We aim to offer practical assistance to overseas patients, as well as a sense of comfort and reassurance” Page 7
“Robotically assisted surgery has transformed how cancers are treated, and The Royal Marsden has driven this change”
“We aim to give patients quick access to the right drugs, without compromising safety”
“There have been staggering advances in the field o reast cancer over the past 20 years”
Page 12
Page 14
Page 8
For referrals and enquiries, call 020 7811 8111 or email privatepatients@rmh.nhs.uk RMPC24_p02-03_Update_v4.0.indd 3
3
13/02/2019 13:10
IN BRIEF In high esteem
Congratulations to Professor David Cunningham, Consultant Medical Oncologist and Head of the Gastrointestinal and Lymphoma Unit, who was awarded an OBE in the 2019 New Year’s Honours list for services to cancer treatment and research. One of the UK’s pre-eminent oncologists, he has made an outstanding contribution to the development of cancer treatment and research.
MR LINAC TREATS FIRST PATIENT
Brexit
F inding new treatments for cancer and improving early detection rates is a global challenge, and we’ re committed to working with European researchers and those further afield for the benefit of cancer patients everywhere – regardless of the B rexit situation. We also pride ourselves on our diverse workforce and will continue to recruit the best talent possible, wherever they are from.
NHS Long Term Plan
As the NHS’s National Cancer Director, our Chief Executive, Cally Palmer, advised the NHS on its Long Term Plan for cancer. Its ambition is that, by 2028, the proportion of cancer patients diagnosed at stages 1 and 2 will rise from the current half to three-quarters. This will mean raising awareness of cancer symptoms, lowering the threshold for referral by GPs, accelerating access to diagnosis and treatment, and maximising screening.
THE ROYAL MARSDEN treated the first patient in the UK using a Magnetic Resonance Linear Accelerator (MR Linac) machine in September. The MR Linac is the first technology in the world to generate magnetic resonance (MR) images and deliver radiotherapy simultaneously – allowing treatment to be adjusted in real time and delivered more accurately and effectively than ever before. This will be particularly
useful when treating tumours that move. Prostate patient Barry Dolling, 65, received radiotherapy treatment on the MR Linac as part of the PRISM clinical trial. He said: “I was really excited to be treated with the MR Linac. The treatment will give me a better quality of life and minimal side effects in comparison to other treatments.” More trials are expected to open later this year.
PIONEER PATIENT Barry Dolling is the first patient in the UK to be treated on the MR Linac
NEW London genomics testing hub The Royal Marsden, in collaboration with G reat Ormond Street H ospital, is to lead the N orth, East and West L ondon partnership (N EW L ondon), one of N H S England’ s seven new laboratory hubs for genomic cancer testing. G enomic testing promises better diagnoses and more effective treatments with fewer side effects.
The Royal Marsden’ s purchase of the Illumina N ovaSeq 6 0 0 0 next-generation seq uencing machine – funded by the Denise Coates F oundation, a supporter of The Royal Marsden Cancer Charity – proved pivotal to the successful bid. The machine can search for cancercausing variants in 2 0 0 genes from over 2 0 0 patients in less than a week.
4 Private Care magazine
RMPC24_p04-05_Update_v4.0.indd 4
13/02/2019 14:04
U P DAT E
A GREAT LEGACY Professor Martin Gore was at the heart of The Royal Marsden’s work
Remembering Martin Gore IT WAS WITH DEEP sadness that we announced the sudden death of Professor Martin Gore CBE in January. Professor Gore was at the heart of life at The Royal Marsden. His contribution as Medical Director for 10 years, as a Trustee of The Royal Marsden Cancer Charity and as a clinician is unparalleled. He was central to our work in cancer research and treatment, and a well-loved friend, colleague and mentor to so many people. During his 40-year career as one of the world’s leading cancer experts, Professor Gore’s vast knowledge helped to save the lives of thousands of cancer patients. Alongside being a professor of cancer medicine
at The Royal Marsden and The Institute of Cancer Research, London, he was also a member of the Commission on Human Medicines at the Medicines and Healthcare products Regulatory Agency, and the Inter-Committee Scientific Advisory Group on Oncology at the European Medicines Agency. He was appointed CBE for his services to oncology in 2016. In a message of condolence, HRH The Duke of Cambridge, President of The Royal Marsden, said: “Martin was such an inspirational man with unparalleled enthusiasm and passion for his work, and I feel privileged to have known him. Back in 2015, he accepted his Lifetime Achievement Award to
a standing ovation throughout the room – reflecting the utmost respect and admiration that everyone at The Royal Marsden held for Martin as a mentor, leader and friend.” Cally Palmer, The Royal Marsden’s Chief Executive, said: “Professor Gore was one of the world’s leading oncologists and devoted his career to improving quality of life and outcomes for all those affected by cancer. He inspired generations of oncologists through his leadership, teaching and training. “His intellect, humour and wisdom and his impact on modern cancer care will be his legacy to patients, the NHS, and cancer research and treatment internationally.”
For referrals and enquiries, call 020 7811 8111 or email privatepatients@rmh.nhs.uk RMPC24_p04-05_Update_v4.0.indd 5
5
19/02/2019 11:54
U P DAT E
More radiotherapy capacity LINEAR ACCELERATOR The new Varian TrueBeam
BETTER TREATMENT FOR RARE CANCER A new approach to treating advanced anal cancer is safer and more effective than the most widely used current treatment, according to the first-ever randomised clinical trial in this group of patients, led by The Royal Marsden. The findings from the InterAACT study, which were presented at the European Society for Medical Oncology Congress in October, will set a new standard of care for this rare type of cancer. They showed that a combination of the chemotherapy drugs carboplatin and paclitaxel is a better option than the current standard. Dr Sheela Rao (above), Consultant Medical Oncologist, who led the study, said: “While treatment with cisplatin and 5-fluorouracil was generally considered a reasonable option for advanced anal cancer, we now know that carboplatin and paclitaxel is more effective and better tolerated. In our study, these patients lived seven months longer overall.”
THANKS TO an investment made by NHS England to upgrade radiotherapy equipment across the country, along with a £1.5million donation from The Royal Marsden Cancer Charity, we now have a third Varian TrueBeam linear accelerator in Chelsea. The TrueBeam delivers all forms of advanced external-beam radiotherapy: image-guided radiotherapy (IGRT); intensitymodulated radiotherapy (IMRT); stereotactic body radiotherapy (SBRT); and volumetric modulated arc therapy (VMAT). Having three units means that we can now treat up to 120 patients with various tumour types – including breast, lung, head and neck, prostate, gastrointestinal and gynaecological cancers – every day.
The Royal Marsden’s Radiotherapy department delivers treatment via 11 linear accelerators – including the three Varian TrueBeams – across both hospital sites, as well as a CyberKnife stereotactic radiotherapy machine, a superficial radiotherapy machine for the treatment of skin cancers, a brachytherapy service, and the UK’s first MR Linac (see page 4).
We can now treat 120 patients with various tumour types every day
6 Private Care magazine
RMPC24_p06-07_Update_International_v4.0.indd 10
19/02/2019 12:01
I N T E R N AT I O N A L S E R V I C E
GOING THE EXTRA MILE
REASSURING PRESENCE Annie Allan supports Chinesespeaking patients
IN YOUR LANGUAGE With The Royal Marsden’s multilingual services, overseas patients receive all the cultural and clinical support they need FOR INTERNATIONAL patients whose first language is not English, having medical treatment in the UK may feel daunting. Our team of specially trained, multilingual staff is on hand to offer support – from the first time patients contact us to the end of treatment. Annie Allan, one of our International Patient Relations Officers, says: “We understand that some patients have made a lot of adjustments, especially those who have travelled to the UK specifically for treatment. I aim to offer practical assistance with our translation and interpreting services, as well as a sense of comfort and reassurance.” Annie supports Chinese-speaking patients and is a constant point of contact between them and clinical staff. She helps set up referral appointments, support visa application processes and guide patients when they first arrive at The Royal Marsden.
“We also help patients to understand what their clinical teams have advised, and importantly interpret the patients’ symptoms and feelings back to the consultants and nurses,” she adds. “Those who have little or no English have expressed sincere appreciation for having someone present who is able to speak their own language.” Annie works closely with a team of multinational colleagues, which includes a dedicated Arabic Advocacy Service. They ensure the needs of international patients, whether cultural or medical, are met. Nuolan, who is undergoing treatment for breast cancer at The Royal Marsden after moving with her husband to the UK from Beijing in 2018, says: “Having someone there to translate into Chinese has been a really important part of my treatment and means that I feel fully informed. During such a difficult time, it has made it much easier for my family.”
Our international team is available to assist patients through all aspects of their treatment – everything from support admission and consultations to advice on accommodation and payment enquiries. We offer translation services for most languages, including Arabic and Mandarin, free of charge. We understand how important it is for patients to feel settled during their time at The Royal Marsden, so we provide them with a range of international newspapers, magazines and TV channels. The team can also help to co-ordinate food for patients, ensuring any dietary requirements – such as halal and kosher meals – are catered to. Furthermore, all our patients are welcome to use our multi-faith prayer and worship room at any time.
FIND OUT MORE
Call +44 (0)20 7808 2063 or email int@rmh.nhs.uk for further details about our international service
For referrals and enquiries, call 020 7811 8111 or email privatepatients@rmh.nhs.uk RMPC24_p06-07_Update_International_v4.0.indd 11
7
13/02/2019 13:37
AWARD-WINNING APPROACHES 8 Private Care magazine
RMPC24_p08-11_LaingBuisson_v5.0.indd 8
19/02/2019 12:06
WHY WE LEAD
ADVANCED TECHNOLOGY Robotic surgery in progress at The Royal Marsden
The Royal Marsden’s success in an unprecedented four categories at the 2018 LaingBuisson Awards, which recognise excellence in private healthcare, is a validation of the exceptional work we do across cancer treatment and care. Here, we take a closer look at the areas we have been commended for
Private Hospital award Robotic surgery As the first hospital in England to introduce the da Vinci Xi robotic surgical system – and now the only centre extensively using two da Vinci Xi models – The Royal Marsden has the most comprehensive programme of robotic surgery for cancer care in the UK. The award in the Private Hospital category for the second successive year recognises our depth of expertise in this area. Our world-leading surgeons have performed 3,000 procedures in the past decade – and treated more than 500 patients in the past year – using robotically assisted techniques. These life-saving interventions have many benefits over conventional surgery, including a reduction in surgical trauma, minimised blood loss and speedier post-operative recovery. Our patients also benefit from a multidisciplinary approach during surgery, with a dedicated and specially trained team – including anaesthetists, specialist nursing staff and consultants – present in theatre.
In 2016, The Royal Marsden Cancer Charity funded the UK’s first multi-speciality Robotic Surgery Fellowship programme, which is training the next generation of surgeons to use the da Vinci Xi to operate across three tumour types – urological, colorectal and gynaecological – rather than just one. We have also established a unique transoral robotic surgery programme, which reduces the time patients spend in theatre and recovery. The Royal Marsden’s team uses the da Vinci Xi to provide better access and visualisation to the back of the mouth and lower down the throat, avoiding incisions to the neck and jaw.
We have performed 3,000 robotic procedures in the past decade
Mr Pardeep Kumar, Consultant Urological Surgeon and Robotic Surgery Lead, says: “In the past decade, robotically assisted surgery has transformed how cancers are treated, and The Royal Marsden has driven this change. The expertise of our staff, the quality of our facilities and the success of our training elevates our status internationally for the benefit of patients.” Nursing Practice award A multidisciplinary team approach for head and neck cancers The Royal Marsden’s multidisciplinary team model ensures a robust and timely diagnosis and personalised treatment plans for all patients, improving their experience and quality of care. In particular, we have an international reputation for the care of cancer patients with complex needs, and this is enhanced by our Altered Airway Multidisciplinary Team (MDT). The Altered Airway MDT ward round is based on national standards of care and research that show that this approach can improve the care of patients with tracheostomies and laryngectomies. Most commonly, patients with altered airways have gastrointestinal or head and neck cancers, and we are seeing increasing numbers of patients with these types of cancers. >
For referrals and enquiries, call 020 7811 8111 or email privatepatients@rmh.nhs.uk RMPC24_p08-11_LaingBuisson_v5.0.indd 9
9
20/02/2019 10:48
POSITIVE ENERGY Ms Marielle Nobbenhuis uses PlasmaJet in theatre, alongside Mr Des Barton
In addition to the daily ward rounds by individual members of the team, the full team – which includes a speech and language therapist, a consultant lead, a dietitian, a physiotherapist, an advanced nurse practitioner, critical care outreach specialists, and ward nurses – visits each patient with an altered airway once a week. “The allied health professional and nurse-led model demonstrated in the MDT is a cost-effective way of providing evidence-based and enhanced care,” says Mo Carruthers, Divisional Nurse Director for Private Care. “In other centres, similar ward rounds are led by the medical team. But at The Royal Marsden, those who are closer
to the patient’s day-to-day needs lead the round. This ensures an improvement in interdisciplinary teamwork and an increased profile within the unit and with patients.” Healthcare Outcomes award PlasmaJet for gynaecological cancer patients Ovarian cancer typically spreads on the surface of organs and tissue in the abdomen and pelvis, which means it is often difficult to surgically remove most or all of the tumour without damaging surrounding tissue. Because of this, surgeons often need to remove parts of the bowel, where the cancer is likely to have spread. This procedure means patients
will require a stoma, which has a significant impact on their quality of life. In 2013, The Royal Marsden became one of the first centres in the UK to introduce the PlasmaJet device, which uses plasma energy from ionised argon gas to cut through and dissect tissue, stop bleeding and destroy cancer cells safely. Unlike other surgical energy devices, PlasmaJet can kill cells on the surface of organs and tissue while leaving healthy parts unaffected, meaning that there is no need to resect or remove these areas. For delicate structures such as the bowel wall, it can safely ‘shave’ off less than a millimetre of tissue, which could not be achieved with
10 Private Care magazine
RMPC24_p08-11_LaingBuisson_v5.0.indd 10
19/02/2019 12:07
WHY WE LEAD
“Without doubt, PlasmaJet has transformed treatment for our patients”
A NOVEL APPROACH Specialist Speech and Language Therapist Lauren LeighDoyle is part of the Altered Airways MDT
any other device without damaging surrounding areas. Not only does this mean that ovarian cancer patients no longer need stomas, it also ultimately improves survival rates. “Without doubt, this has transformed treatment for our patients,” says Ms Marielle Nobbenhuis, Consultant Gynaecological Oncology Surgeon. “With PlasmaJet, not only can surgeons completely remove or destroy all visible
disease, it also means there is less need for bowel resection. “This offers the potential for actually curing these patients, as well as allowing us to treat areas of disease that couldn’t otherwise be treated.” High Growth award The unique model of partnership between the private and NHS sectors Private Care at The Royal Marsden is a unique proposition. It provides patients with access
to the research, clinicians, governance structures, facilities, treatment and care of an NHS hospital combined with the hospitality, speed and service of a private centre. By integrating our NHS and Private Care services, The Royal Marsden benefits from economies of scale, greater purchasing power, lower overheads and the ability to attract world-leading consultants who can conduct their NHS, private and research practices under one roof. These benefits are passed on to the patient, with access to the latest treatments and expert clinicians and their cancer pathways being conducted in one place. In addition, all of the profit generated by The Royal Marsden Private Care is reinvested into the NHS Foundation Trust. This money is used to fund new technology, equipment and research, and to continuously improve quality of care for both NHS and private patients alike.
For referrals and enquiries, call 020 7811 8111 or email privatepatients@rmh.nhs.uk RMPC24_p08-11_LaingBuisson_v5.0.indd 11
11
19/02/2019 12:07
PUTTING PATIENT SAFETY FIRST The Royal Marsden offers private patients the unique benefits of an NHS hospital, including a robust system of governance that ensures treatments are safe and effective PLAYING BY THE RULES Jatinder Harchowal (left); Mr Asif Chaudry (above right); Pat Cattini (right)
RECEIVING PRIVATE CANCER care in an NHS setting has key benefits for patients at The Royal Marsden, giving them the confidence that stems from treatment decisions being made by multidisciplinary specialists, and access to a world-class critical care ward. Private patients can also rest assured that all aspects of their care – from prescribed drugs to the radiotherapy or surgery they have – has been reviewed and approved as part of the tight governance framework required of an NHS hospital.
“All new drugs, and new indications for previously approved drugs, must be reviewed by the Drugs and Therapies Committee prior to use within the Trust,” says Chief Pharmacist Jatinder Harchowal, recently nominated for the LaingBuisson Rising Star award. “This amounts to a unique safety net. “In the private setting at The Royal Marsden, treatment decisions follow the same local requirements for clinical governance as they do for the NHS.”
Consultants must co-write a clinical review with a pharmacist and present their case, accompanied by at least two peer-reviewed papers demonstrating the drug’s safety and efficacy, to the committee. Chaired by Consultant Haematologist Dr Sunil Iyengar and comprising a combination of consultants, pharmacists and nurses, the committee then carries out a multidisciplinary review, scrutinising the data and challenging the case to ensure that all relevant experts agree
12 Private Care magazine
RMPC24_p12-13_Governance_v4.0.indd 12
19/02/2019 12:08
G OV E R N A N C E
MR ASIF CHAUDRY
that the drug is effective, safe and fit for clinical use. Jatinder says: “We aim to give patients quick access to the right drugs for them, without compromising safety.” The benefit of experience Similarly, The Royal Marsden pioneers surgical techniques and proves their efficacy through research, without putting patients at risk. The Trust has the most comprehensive programme of robotic surgery for cancer in the UK, and is the only centre to offer robotic oesophagectomies and perform free-flap surgery for head and neck cancers. Consultant Surgeon Mr Asif Chaudry explains that surgeons who have the benefit of the NHS’s experience behind them are forever conscious not to take risks unduly. “NHS England has the longest internal memory of any healthcare provider, and a length and breadth of experience in risk modification and mitigation smaller entities don’t have,” he says. “In surgery, we use this to our advantage, learning from what has gone before and ensuring we continually evaluate the efficacy of our work.” Professor David Nicol, Consultant Urologist and Chief of Surgery, adds: “Thanks to strict regulations, surgeons with the most experience and the best training work for the NHS. This benefits all patients at The Royal Marsden, whether NHS or private.” Every piece matters Every item of equipment a Royal Marsden patient has contact with has been approved
Consultant Surgeon Mr Chaudry and his colleague Mr Myles Smith undertook an extensive two-year training and regulation process before performing the UK’s first robotic oesophagectomy at The Royal Marsden. This involved: Presenting an efficacy case to the Robotic User Group committee, setting out the patient benefits Seeking support from senior colleagues and the Medical Director Completing 60 hours of online learning modules and simulation at the da Vinci Xi console, followed by theatre simulation, with Intuitive, the maker of the da Vinci surgical systems
“NHS England has experience in risk modification and mitigation that smaller entities don’t have” as safe and effective, says Pat Cattini, Lead Nurse for Infection Prevention and Control. “New devices have to be rubber-stamped by the Medical Device Committee, who assess the clinical benefit; as well as Procurement, who assess the efficiency; and must comply with strict infection prevention and control requirements,” she explains. “Whether it’s a new scope costing £20,000 or the cotton swabs we use, everything is carefully considered for its safety and effectiveness.”
Bespoke training under Professor Richard van Hillegersberg, who pioneered the procedure at University Medical Center Utrecht. Entry required proficiency in oesophageal and minimally invasive surgery before moving to robotic procedures Achieving a score of over 90 per cent when executing the procedure in training Performing a case at The Royal Marsden – with patient consent – within two weeks of gaining approval. Six more cases within eight weeks followed, attended by proctors from Utrecht to guide and monitor progress
For referrals and enquiries, call 020 7811 8111 or email privatepatients@rmh.nhs.uk RMPC24_p12-13_Governance_v4.0.indd 13
13
19/02/2019 12:08
DR ALISTAIR RING Consultant in Medical Oncology RECENTLY NOMINATED for the LaingBuisson Rising Star award, Dr Alistair Ring, Consultant in Medical Oncology, is one of the leading breast experts at The Royal Marsden. After qualifying in 1997, Dr Ring completed his oncology training at The Royal Marsden, St George’s and Guy’s hospitals in London. He became a consultant in 2008 before joining The Royal Marsden in 2014. Today, he specialises in all aspects of the medical treatment of breast cancer, and has a particular expertise in the management of metastatic and early breast cancer, and the management of cancer in older patients. Throughout his medical career, Dr Ring has been at the forefront of major research. He
gained his MD research degree in 2005 from The Institute of Cancer Research, London (ICR) and has become the UK lead for a number of pioneering research studies. Much of his work examines novel treatments and targeted therapies, more recently looking at the roles of aspirin and modern targeted drugs in managing breast cancer. Dr Ring continues to explore new treatment avenues with the aim of developing more effective personalised treatments that improve patient survival and quality of life. He is now working alongside researchers from the ICR on the plasmaMATCH trial, which aims to use blood tests to match breast cancer patients with the most effective treatments.
CAREER HIGHLIGHTS 1991-97 Pre-clinical and clinical training at the University of Cambridge and University of Oxford 1997-2008 Undertakes oncology training at The Royal Marsden, St George’s and Guy’s hospitals, London 2008 Appointed Senior Lecturer in Oncology at Brighton
Q&A and Sussex Medical School, where he was also appointed Director of the Brighton NIHR Clinical Research Facility 2014 Appointed as a Consultant Medical Oncologist at The Royal Marsden 2017 Editor of the textbook Breast Cancer Survivorship
Q How has the treatment of breast cancer changed during your career? A There have been staggering advances in the field of breast cancer over the past 20 years. We have made major progress in the development of targeted therapies, thanks to a better understanding of the molecular abnormalities in cancer cells. This means we can offer
14 Private Care magazine
RMPC24_p14-15_consultant_v4.0.indd 14
19/02/2019 12:09
C O N S U LTA N T F O C U S
“Looking after the holistic needs of patients, and improving quality of life – during and after treatment – is key” Q Why is early diagnosis of breast cancer so important? A By improving the accuracy of early detection, we expect to see more and more patients surviving breast cancer. Early diagnosis requires a shift towards faster investigation and quicker responses to patients who present with symptoms, and we are engaged in a variety of services that offer this. Importantly, we aim to provide patients with fast and direct access to worldleading diagnostic experts, in an easily accessible and reassuring environment.
patients more personalised treatment options, with reduced toxicity and better outcomes. Q What services do you provide at The Royal Marsden? A We have a talented multidisciplinary team. Patients benefit from a comprehensive service provided by national and international specialists. I work with patients from diagnosis to establish an appropriate and individualised treatment plan.
Q Why is research important for your area of expertise? A We lead innovative research studies on a national and international scale, which we hope will lead to better survival and quality of life. I am currently leading three studies that could affect the routine management of the 50,000 women diagnosed with breast cancer every year in the UK. My expertise also lies in the needs of elderly patients with cancer. We are leading the National Institute for Health Research (NIHR) Bridging the Age Gap study, which has developed tools to help patients and doctors make more informed decisions about breast cancer
treatment and increase the uptake of surgery and chemotherapy in older women with breast cancer. These tools are now being tested in a study involving more than 3,000 patients. Q What does the future of breast cancer treatment hold? A It’s crucial that we prepare the clinicians of the future, and I was recently lead editor on the Breast Cancer Survivorship textbook. It’s aimed at the next generation of oncologists, discussing the impact on patients of diagnosis and treatment of early breast cancer. Despite the incidence of breast cancer increasing, survival rates are also increasing. There are a number of reasons for this – largely early diagnosis, better surgical techniques and increasing use of adjuvant therapies. Looking after the holistic needs of patients, and improving quality of life – during and after treatment – is key. For those patients with advanced – or metastatic – breast cancer, our focus remains on controlling the cancer for as long as possible and maintaining quality of life. We also continue to investigate new options for when other treatment is unsuccessful.
For referrals and enquiries, call 020 7811 8111 or email privatepatients@rmh.nhs.uk RMPC24_p14-15_consultant_v4.0.indd 15
15
13/02/2019 14:30
As Europe’s largest cancer centre, The Royal Marsden has the expertise, facilities and technology to provide the highest standards of personalised care, and we treat more private patients than any other UK centre. By choosing The Royal Marsden, you are ensuring the best possible treatment and care, at the moment a patient needs it most. Because where a patient goes first really matters.
Life demands excellence
To refer a private patient, contact our Central Referral and Information Line on +44 (0)20 7811 8111 or email privatepatients@rmh.nhs.uk royalmarsden.nhs.uk/private
RMPC24_p16_back cover_v1.0.indd 1
13/02/2019 16:27